Treatment of anaemia due to cytotoxic chemotherapy

Prescrire International

Volumn 11, Issue 58, 2002, Pages 39-43

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH FACTOR; CYTOTOXIC AGENT; FLUOROURACIL; FOLINATE CALCIUM; HEMOGLOBIN; PLACEBO; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; BONE MARROW TOXICITY; CANCER; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; DATA ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG STORAGE; EDEMA; HEMATOLOGIC MALIGNANCY; HORMONAL REGULATION; HUMAN; HYPERTENSION; LICENSING; NEPHROTOXICITY; QUALITY OF LIFE; RISK ASSESSMENT; ROOM TEMPERATURE; SCORING SYSTEM; STANDARD; THROMBOSIS;

EID: 0037941095     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Prescrire Rédaction "époétine alfa, nouvelle indication-Eprex°" Rev Prescr 1996; 16 (160): 206-207.
2. Prescrire Rédaction "époétine bêta et anémies dues aux chimiothérapies à base de platine-NeoRecormon°" Rev Prescr 1998; 18 (188): 660-662.
3. Case DC et al. "Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy" J Natl Cancer Inst 1993; 85 (10): 801-806.
4. Harper PG "Clinical expert report - Epoetinum alfa (Eprex°; érypo°) - Part I, volume I" 9 June 1999: 64-101 + 159-179.
5. Littlewood TJ et al. "Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, place-bo-controlled trial" J Clin Oncol 2001: 19 (11): 2865-2874.
6. Dammacco F et al. "Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma" Br J Haematol 2001; 113 (1): 172-179.
7. French agency for health product safety "Résumé des caractéristiques du produit - Eprex 4 000 UI" 22 March 2000: 14 pages.
8. "Epogen". In: "Physicians' Desk Reference" Medical Economics Company, Montvale 2001: 542-548.
9. Cazzola M et al. "Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response" Blood 1995; 86 (12): 4446-4453.
10. Österborg A et al. "Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma. A randomized multicenter study" Blood 1996; 87 (7): 2675-2682.
11. "NeoRecormon". In French datasheet compendium: "Dictionnaire Vidal" OVP Éditions du Vidal, Paris 2001: 1396-1398.
12. Gabrilove JL et al. "Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing" J Clin Oncol 2001; 19 (11): 2875-2882.
13. Demetri GD et al. "Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study" J Clin Oncol 1998; 16 (10): 3412-3425.
14. Glaspy J et al. "Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice" J Clin Oncol 1997; 15 (3): 1218-1234.